Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast Cancer

22 Jul 2024

Abstract excerpt

Poly(ADP-ribose) polymerase (PARP) inhibitors are targeted therapies that accumulate DNA damage by interfering with DNA repair mechanisms and are approved for treating several cancers with BRCA1/2 mutations. In this study, we utilized CRISPR-dCas9 interference screening to identify genes regulating sensitivity to PARP inhibitors in breast cancer cell lines. Our findings indicated that the interferon (IFN)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39062738
DOI: 10.3390/genes15070959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Role of IRF9 Upregulation in Modulating Sensitivity to Olaparib and Platinum-Based Chemotherapies in Breast CancerPMID 39062738Read ↗

Cancer Cell Resistance to IFNγ Can Occur via Enhanced Double-Strand Break Repair Pathway ActivitySemantic proximity Read ↗

Machine learning-based prediction of response to PARP inhibition across cancer typesSemantic proximity Read ↗

MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancerSemantic proximity Read ↗

Downregulation of the splicing regulator NSRP1 confers resistance to CDK4/6 inhibitors via activation of interferon signaling in breast cancerSemantic proximity Read ↗

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitorsSemantic proximity Read ↗

SETD1A-dependent EME1 transcription drives PARPi sensitivity in HR deficient tumour cellsSemantic proximity Read ↗

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparibSemantic proximity Read ↗

<i>BRCA2</i> abrogation triggers innate immune responses potentiated by treatment with PARP inhibitorsSemantic proximity Read ↗

A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 InhibitorSemantic proximity Read ↗

ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinomaSemantic proximity Read ↗

ATF3-induced activation of the NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinomaSemantic proximity Read ↗

Modulation of SLFN11 induces changes in DNA Damage responseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.